Avalo Therapeutics Inc

NASDAQ:AVTX 4:00:00 PM EDT

0.16

+0.04 (+36.74%)

6:16:50 PM EDT: $0.17 +0.01 (+4.85%)

Market Cap (Intraday)	3.41M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1 Million
Adjusted EPS	-$1.10

See more estimates

10-Day MA	$0.13
50-Day MA	$0.16
200-Day MA	$2.39

See more pivots

Avalo Therapeutics Inc Stock, NASDAQ:AVTX

540 Gaither Road, Suite 400, Rockville, Maryland 20850

United States of America

Phone: +1.410.522.8707

Number of Employees: 20

http://www.avalotx.com

Description

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.